Primary Total: $52,502,661
Total: $42,538,086
Primary Total: $39,077,134
Total: $1,476,293
Primary Total: $74,881
*Social Cognition Following Right Hemisphere Stroke, (426015), Neurological Communicative Disorders and Stroke, $104,596 (adjustment).
*University of Cincinnati Aids Clinical Trials Unit, (429769), Univ of Cincinnati, $77,984.
*A Trial of Recombinant Methionyl Human Brain-Derived Neurotropic Factor (r-met BDNF) Given by Daily Subcutaneous Injection to Patients with Amyotrophic Lateral Sclerosis Part C, (433350), AMGen, $131,129.
*An Open Label Safety Study of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metBDNF) Given by Daily Subcutaneous Injection to Patients with Amytrophic Lateral Sclerosis, (428847), AMGen, $19,799 (adjustment).
*An Active Treatment Study of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metHuBDNF) Given by Daily Subcutaneous Injections to Patients with Amyotrophic Lateral Sclerosis (ALS), (460093), AMGen, $2.
*A Trial of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-met HuBDNF) Given by Daily Subcutaneous Injections to Patients in Amyotrophic Lateral Sclerosis (ALS), (427975), AMGen, $217,375 (adjustment).
*Biomarkers of Brain Aging, (433372), Natl Institute on Aging, $1,640.
*Biomarkers of Brain Aging, (426995), Natl Institute on Aging, $241,831 (adjustment).
Stroke Trends and Distribution: United States, 1900-1990, (428628), Natl Institute of Neurological Diseases & Stroke, $74,879 (adjustment).
*Mechanisms of Brain Injury and Its Systemic Sequelae, (433082), Natl Institute of Neurological Diseases & Stroke, $149,250 (adjustment).
*Calpain and Excitotoxicity in Focal Cerebral Ischemia, (429747), American Health Assistance Fdtn, $15,000.
*Patent Foramen Ovale in Cryptogenic Stroke (PICSS), (429874), Columbia Univ, $5,000.
*Antiphospholipid Antibodies and Stroke, (427702), Henry Ford Hospital for APASS Consortium, $1,100 (adjustment).
*Microtubular Proteolysis in Cerebral Ischemia, (429277), Natl Institute of Neurological Diseases & Stroke, $292,220.
*Double-Blind, Randomized, Placebo-Controlled, Parallel- Group Trial of the Efficacy of Enlimomab (Anti-ICAM-1) Compared to Placebo Administered Within 6 hours of the Onset of Stroke Symptoms of Treatment of Acute Ischemic Stroke, (428573), Boehringer Ingelheim, $121,769 (adjustment).
*A Placebo-Controlled Study to Determine the Effects of 500mg, 1000mg, and 2000mg Citicoline in Ischemic Stroke Patients, (428018), Parexel International Co, $51,167 (adjustment).
*CERVENE Modification of Outcome in Patients with Acute Ischemic Stroke, (429615), Baker Norton Pharmaceuticals, $31,916.
*Instrumentation Protocol, (433347), Univ of California San Diego, $30,000.
*Alzheimer's Disease Cooperative Study Unit, (426468), Univ of California San Diego, $10,858 (adjustment).
*A Placebo-Controlled Study of Acetyl-1-Carnitine in Patients with Alzheimer's Disease: A Multi-Center Study, (424813), Sigma Tau Pharmaceuticals, $4,675 (adjustment).
*Selegiline (Deprenyl) Protocol, (433285), Univ of California San Diego, $14,782.
*Selegiline (Deprenyl) Protocol, (426881), Univ of California San Diego, $56,219 (adjustment).
Neurontin Steps (Study of Titration to Effectiveness and Profile of Safety), (429382), Parke Davis, $2.
*Safety and Efficacy of Tiagabine HCL Monotherapy in the Treatment for Partial Seizures: High Dose Versus Low Dose, (427742), Abbott Laboratories, $6,480 (adjustment).
For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )
Last Updated: 6/30/03